Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipid A is the highly conserved, hydrophobic anchor of lipopolysaccharide (LPS) found in the outer membrane of almost all Gram-negative bacteria (PMID: 12110610). It serves as the primary endotoxic component of LPS, recognized by the human innate immune system via the Toll-like receptor 4 (TLR4) and myeloid differentiation factor 2 (MD-2) complex (PMID: 19349967). Upon recognition, it triggers the release of pro-inflammatory cytokines, which is essential for clearing infections but can lead to life-threatening sepsis and septic shock if the response is systemic (StatPearls: Sepsis). In clinical medicine, Lipid A is a critical target for last-resort antibiotics like polymyxins, which bind to its phosphate groups to destabilize the bacterial cell wall (PMID: 23432315). Furthermore, research into Lipid A analogs has led to the development of vaccine adjuvants and potential treatments for endotoxemia (PubChem CID 11960511).
Direct binding to the lipid A moiety to disrupt the bacterial outer membrane or to neutralize its ability to activate the TLR4/MD-2 complex (PMID: 23432315).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide lipid A domain (Lipid A).